仲某某
Lv52
960 积分
2021-12-17 加入
-
Pathological response following long‐course neoadjuvant chemoradiotherapy for locally advanced rectal cancer
4天前
已完结
-
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
22天前
已完结
-
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
22天前
已完结
-
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma
1个月前
已完结
-
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
1个月前
已完结
-
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
1个月前
已完结
-
Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial
1个月前
已完结
-
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
4个月前
已完结
-
Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer
4个月前
已完结
-
Mismatch Repair Deficiency, Microsatellite Instability, and Survival
4个月前
已完结